148 related articles for article (PubMed ID: 29512744)
1. Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model.
Xia LJ; Wu YL; Ma J; Zhang FC
Mol Med Rep; 2018 May; 17(5):6245-6252. PubMed ID: 29512744
[TBL] [Abstract][Full Text] [Related]
2. CecropinXJ inhibits the proliferation of human gastric cancer BGC823 cells and induces cell death in vitro and in vivo.
Wu YL; Xia LJ; Li JY; Zhang FC
Int J Oncol; 2015 May; 46(5):2181-93. PubMed ID: 25826779
[TBL] [Abstract][Full Text] [Related]
3. Expression, purification and characterization of cecropin antibacterial peptide from Bombyx mori in Saccharomyces cerevisiae.
Xia L; Liu Z; Ma J; Sun S; Yang J; Zhang F
Protein Expr Purif; 2013 Jul; 90(1):47-54. PubMed ID: 23500722
[TBL] [Abstract][Full Text] [Related]
4. CecropinXJ, a silkworm antimicrobial peptide, induces cytoskeleton disruption in esophageal carcinoma cells.
Xia L; Wu Y; Kang S; Ma J; Yang J; Zhang F
Acta Biochim Biophys Sin (Shanghai); 2014 Oct; 46(10):867-76. PubMed ID: 25122621
[TBL] [Abstract][Full Text] [Related]
5. The antibacterial peptide from
Xia L; Wu Y; Ma JI; Yang J; Zhang F
Oncol Lett; 2016 Jul; 12(1):57-62. PubMed ID: 27347099
[TBL] [Abstract][Full Text] [Related]
6. Role of soluble β-(1-3),(1-6)-D-glucan from Saccharomyces cerevisiae in the murine P388 ascites tumor model.
Harnack U; Eckert K; Pecher G
In Vivo; 2011; 25(2):185-9. PubMed ID: 21471533
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.
Kobayashi M; Sakamoto J; Namikawa T; Okamoto K; Okabayashi T; Ichikawa K; Araki K
World J Gastroenterol; 2006 Mar; 12(9):1412-5. PubMed ID: 16552811
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
Kasai S; Kuwayama N; Motoo Y; Kawashima A; Matsumoto K; Yano S; Matsushima K; Yasumoto K
Biochem Biophys Res Commun; 2022 Apr; 600():80-86. PubMed ID: 35196631
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of Bombyx mori antimicrobial peptide cecropins on esophageal cancer cells.
Xu P; Lv D; Wang X; Wang Y; Hou C; Gao K; Guo X
Eur J Pharmacol; 2020 Nov; 887():173434. PubMed ID: 32763299
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites.
Ba MC; Cui SZ; Lin SQ; Tang YQ; Wu YB; Wang B; Zhang XL
World J Gastroenterol; 2010 Apr; 16(15):1901-7. PubMed ID: 20397270
[TBL] [Abstract][Full Text] [Related]
11. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer.
Imamoto H; Oba K; Sakamoto J; Iishi H; Narahara H; Yumiba T; Morimoto T; Nakamura M; Oriuchi N; Kakutani C; Morita S; Shiozaki H
Gastric Cancer; 2011 Mar; 14(1):81-90. PubMed ID: 21327925
[TBL] [Abstract][Full Text] [Related]
12. Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin.
Ohbatake Y; Fushida S; Tsukada T; Kinoshita J; Oyama K; Hayashi H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Yashiro M; Hirakawa K; Ohta T
Clin Exp Med; 2016 Nov; 16(4):585-592. PubMed ID: 26359244
[TBL] [Abstract][Full Text] [Related]
13. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
Zhao L; Yasumoto K; Kawashima A; Nakagawa T; Takeuchi S; Yamada T; Matsumoto K; Yonekura K; Yoshie O; Yano S
Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and antioxidant status of the methanol extract of Careya arborea bark against Dalton's lymphoma ascites-induced ascitic and solid tumor in mice.
Natesan S; Badami S; Dongre SH; Godavarthi A
J Pharmacol Sci; 2007 Jan; 103(1):12-23. PubMed ID: 17251685
[TBL] [Abstract][Full Text] [Related]
15. [In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites].
Geng M; Ma T; YeE ZB; Ji YB; Lou GY; Xi WQ; Jiang JS; Xia HQ; Li H
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):460-3. PubMed ID: 17152496
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study on CPT-11 intraperitoneal chemotherapy--metabolism of CPT-11 in malignant ascites].
Maruyama M; Toukairin Y; Baba H; Yoshida T; Kure N; Nagahama T; Ebuchi M
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1858-60. PubMed ID: 11086430
[TBL] [Abstract][Full Text] [Related]
17. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites.
Cui S; Ba M; Tang Y; Liu J; Wu Y; Wang B; Zhang X; Tang H; Zhong S
Oncol Rep; 2012 Oct; 28(4):1325-31. PubMed ID: 22797826
[TBL] [Abstract][Full Text] [Related]
18. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
[TBL] [Abstract][Full Text] [Related]
19. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites.
Barni S; Cabiddu M; Ghilardi M; Petrelli F
Crit Rev Oncol Hematol; 2011 Aug; 79(2):144-53. PubMed ID: 20708947
[TBL] [Abstract][Full Text] [Related]
20. SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation.
Bin Y; Lan D; Bao W; Yang H; Zhou S; Huang F; Wang M; Peng Z
Trials; 2022 Mar; 23(1):211. PubMed ID: 35279214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
